These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 32692450)

  • 1. Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer.
    Karasic TB; O'Hara MH; Teitelbaum UR; Damjanov N; Giantonio BJ; d'Entremont TS; Gallagher M; Zhang PJ; O'Dwyer PJ
    Oncologist; 2020 Dec; 25(12):e1864-e1868. PubMed ID: 32692450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.
    Clark AS; Hong F; Finn RS; DeMichele AM; Mitchell EP; Zwiebel J; Arnaldez FI; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Copur MS; Kasbari SS; Thind R; Conley BA; Arteaga CL; O'Dwyer PJ; Harris LN; Chen AP; Flaherty KT
    Clin Cancer Res; 2023 Apr; 29(8):1477-1483. PubMed ID: 36853016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407).
    Grande E; Teulé A; Alonso-Gordoa T; Jiménez-Fonseca P; Benavent M; Capdevila J; Custodio A; Vera R; Munarriz J; La Casta A; Díez JJ; Gajate P; Molina-Cerrillo J; Matos I; Cristóbal EM; Ruffinelli JC; Palacios J; García-Carbonero R
    Oncologist; 2020 Sep; 25(9):745-e1265. PubMed ID: 32045050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma.
    Horbinski C; Xi G; Wang Y; Hashizume R; Gopalakrishnan M; Phillips JJ; Houghton P; James CD; Kalapurakal JA
    Neurooncol Adv; 2021; 3(1):vdab085. PubMed ID: 34345820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
    N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma.
    Zhou J; Wu Z; Zhang Z; Goss L; McFarland J; Nagaraja A; Xie Y; Gu S; Peng K; Zeng Y; Zhang X; Long H; Nakagawa H; Rustgi A; Diehl JA; Meyerson M; Wong KK; Bass A
    Gut; 2022 Apr; 71(4):665-675. PubMed ID: 33789967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Dennis MJ; Sacco AG; Qi Y; Bykowski J; Pittman E; Chen R; Messer K; Cohen EEW; Gold KA
    Oral Oncol; 2022 Dec; 135():106219. PubMed ID: 36279618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
    Sacco AG; Chen R; Worden FP; Wong DJL; Adkins D; Swiecicki P; Chai-Ho W; Oppelt P; Ghosh D; Bykowski J; Molinolo A; Pittman E; Estrada MV; Gold K; Daniels G; Lippman SM; Natsuhara A; Messer K; Cohen EEW
    Lancet Oncol; 2021 Jun; 22(6):883-892. PubMed ID: 33989559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
    Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
    Catenacci DV; Rosales M; Chung HC; H Yoon H; Shen L; Moehler M; Kang YK
    Future Oncol; 2021 Apr; 17(10):1155-1164. PubMed ID: 33263418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects.
    Sabatelle RC; Colson YL; Sachdeva U; Grinstaff MW
    Mol Pharm; 2024 Jul; 21(7):3103-3120. PubMed ID: 38888089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Eukaryotic Initiating Factor eIF4E Overcomes Abemaciclib Resistance in Gastric Cancer.
    Zha HL; Chen W; Shi W; Liao YY
    Curr Med Sci; 2023 Oct; 43(5):927-934. PubMed ID: 37752406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclers' kinases in cell division: from molecules to cancer therapy.
    Milletti G; Colicchia V; Cecconi F
    Cell Death Differ; 2023 Sep; 30(9):2035-2052. PubMed ID: 37516809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palbociclib-Induced Cellular Senescence Is Modulated by the mTOR Complex 1 and Autophagy.
    Cayo A; Venturini W; Rebolledo-Mira D; Moore-Carrasco R; Herrada AA; Nova-Lamperti E; Valenzuela C; Brown NE
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma.
    Ooki A; Osumi H; Chin K; Watanabe M; Yamaguchi K
    Ther Adv Med Oncol; 2023; 15():17588359221138377. PubMed ID: 36872946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer.
    Javed A; Yarmohammadi M; Korkmaz KS; Rubio-Tomás T
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma.
    Feng M; Xu H; Zhou W; Pan Y
    J Exp Clin Cancer Res; 2023 Feb; 42(1):44. PubMed ID: 36755269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase 4/6 inhibitor-associated thromboembolism: a critical evaluation of the current evidence.
    Watson NW; Shatzel JJ; Al-Samkari H
    J Thromb Haemost; 2023 Apr; 21(4):758-770. PubMed ID: 36696184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug repositioning for esophageal squamous cell carcinoma.
    Bennett AN; Huang RX; He Q; Lee NP; Sung WK; Chan KHK
    Front Genet; 2022; 13():991842. PubMed ID: 36246638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approach to Localized Squamous Cell Cancer of the Esophagus.
    Weidenbaum C; Gibson MK
    Curr Treat Options Oncol; 2022 Oct; 23(10):1370-1387. PubMed ID: 36042147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.